Military Spending Spurs Interest In Research on Biological Weapons

Date: December 15, 1986 BOSTON-A sharp increase in U.S. military spending for research on biological warfare agents has raised concern about its effect on related fields and sparked debate on the nature of the work. The Defense Department expects to spend $73.2 million in 1987 on biological weapons research, a figure that has risen from $14.9 million at the start of the Reagan administration. Douglas Feith, former Deputy Assistant Secretary of Defense for Negotiations Policy, told a House sub-co

Written bySeth Shulman
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Date: December 15, 1986

BOSTON-A sharp increase in U.S. military spending for research on biological warfare agents has raised concern about its effect on related fields and sparked debate on the nature of the work.

The Defense Department expects to spend $73.2 million in 1987 on biological weapons research, a figure that has risen from $14.9 million at the start of the Reagan administration. Douglas Feith, former Deputy Assistant Secretary of Defense for Negotiations Policy, told a House sub-committee last summer that "the prevailing judgment of years ago that BW is not a militarily significant weapon is now quite un sustainable."

Most of this research focuses on the development of vaccines against some of the most deadly and exotic diseases known-diseases that could be unleashed as part of a biological warfare (BW) campaign. And while much of this research takes place at in-house Army, Navy and Air Force re search ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies